Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Clinical Trial to Evaluate the Effects of Glow Shakes Premium Collagen Meal Replacement on Nutritional Adequacy, Body Composition, Skin Health, Satiety, and Overall Wellness in Adults Using GLP-1 or Dual-Incretin Medications for Weight Management

12 de noviembre de 2026 actualizado por: The Collagen Co. - GLP-1 Users

This is a single-group, open-label, decentralized clinical trial evaluating the effects of 12 weeks of once-daily consumption of Glow Shakes Premium Collagen Meal Replacement on nutritional adequacy, body composition, skin health, satiety, and overall wellness in 40 adults aged 18-55 years who are currently using a GLP-1 receptor agonist or dual-incretin medication for weight management. All study activities are conducted remotely; participants complete questionnaire assessments and smart scale body composition measurements at home at Baseline, Week 4, Week 8, and Week 12.

Participants replace a typical meal once daily with the study product for 12 consecutive weeks while continuing their existing GLP-1 or dual-incretin medication. The primary objective is to evaluate within-participant change in perceived nutritional adequacy from Baseline to Week 12. Secondary objectives include changes in body fat percentage, muscle mass, perceived skin health, hunger and satiety, hair health, energy and cognitive focus, nail health, gut comfort, metabolism support, physical strength, and product tolerability and satisfaction.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89101
        • Citruslabs

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults aged 18-55 years at the time of enrollment.
  • Currently using a GLP-1 receptor agonist or dual-incretin medication for weight management (e.g., semaglutide, tirzepatide, liraglutide) for a minimum of 4 weeks at the time of enrollment, with a stable or documented dose (no dose change within the 4 weeks prior to enrollment).
  • Self-reported interest in supporting weight management, lean muscle maintenance, nutritional adequacy, or beauty-related benefits (e.g., skin, hair, nails) during GLP-1 therapy.
  • Willing and able to use Glow Shakes Premium Collagen Meal Replacement as a once-daily meal replacement (replacing a typical meal) for 12 consecutive weeks and to complete all questionnaire assessments and Withings smart scale body composition measurements at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to maintain current GLP-1 or dual-incretin medication dose throughout the study duration without planned dose adjustments (except in the event of a medically indicated change).
  • Willing to maintain current diet (except for the study product), exercise routine, and lifestyle habits for the duration of the 12-week study, without introducing any new supplements or products specifically targeting weight loss, appetite, or body composition.
  • In good general health.
  • Resides in the United States.

Exclusion Criteria:

  • Pregnant or breastfeeding at the time of enrollment, or planning to become pregnant during the 12-week study period.
  • Known allergy or intolerance to any ingredient in the Glow Shakes formulation, including milk, whey, or collagen-derived ingredients.
  • Diagnosed with a serious medical condition requiring medical nutritional management, including but not limited to Type 1 diabetes, active cancer, or severe renal or hepatic disease.
  • Currently testing, or plan to in the next 12 weeks, a product for another research study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Glow Shakes Premium Collagen Meal Replacement Arm

Participants will consume one serving once daily - replacing a typical meal such as breakfast or lunch - for 12 consecutive weeks. One serving is prepared by adding the powder to 11.8 fl oz (approximately 350 mL) of water: add water first, then two scoops of powder, and shake for fewer than 10 seconds. Drink immediately after preparation.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Perceived Nutritional Adequacy
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived nutritional adequacy assessed via self-report questionnaire

Baseline to Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Body Fat Percentage
Periodo de tiempo: Baseline to Week 12

Within-participant change in body fat percentage (%) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Muscle Mass
Periodo de tiempo: Baseline to Week 12

Within-participant change in muscle mass (kg) measured by participant self-administered Withings smart scale

Baseline to Week 12
Change in Self-Reported Weight Management and Food Cravings
Periodo de tiempo: Baseline to Week 12

Within-participant change assessed via the validated Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Perceived Skin Smoothness
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived skin smoothness score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Perceived Skin Elasticity
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived skin elasticity score assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hunger Intensity
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived hunger intensity assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Satiety Duration
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived satiety duration assessed via visual analogue scale or equivalent validated hunger/satiety instrument

Baseline to Week 12
Change in Self-Reported Food Craving Scores
Periodo de tiempo: Baseline to Week 12

Within-participant change in food craving scores assessed via the Food Cravings Questionnaire-Trait Reduced (FCQ-T-reduced)

Baseline to Week 12
Change in Self-Reported Hair Thickness
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived hair thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Hair Health
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived hair health assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Energy Levels
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived energy levels assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Cognitive Focus
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived cognitive focus assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Thickness
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived nail thickness assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Nail Health
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived nail health assessed via self-report questionnaire

Baseline to Week 12
Change in Gut Comfort and Digestive Health
Periodo de tiempo: Baseline to Week 12

Within-participant change in gut comfort and digestive symptom scores assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Metabolism Support
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived metabolism support assessed via self-report questionnaire

Baseline to Week 12
Change in Self-Reported Physical Strength
Periodo de tiempo: Baseline to Week 12

Within-participant change in perceived physical strength assessed via self-report questionnaire

Baseline to Week 12
Product Tolerability and Participant Satisfaction
Periodo de tiempo: Week 12

Participant-reported product satisfaction, acceptability, and tolerability assessed via product satisfaction questionnaire

Week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de enero de 2027

Finalización del estudio (Estimado)

1 de enero de 2027

Fechas de registro del estudio

Enviado por primera vez

12 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • THECO-73657

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .